EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Systemic and coronary hemodynamic effects of the new hypotensive drug l 6150






Journal of International Medical Research 4(6): 402-409

Systemic and coronary hemodynamic effects of the new hypotensive drug l 6150

The acute systemic and coronary hemodynamic effects of a new hypotensive drug L 6150 (3-hydrazino-6-[N,N-bis(2-hydroxyethyl)amino]pyridazine) were studied in 6 patients with renal or essential hypertension. The drug, administered i.v. at a dose of 2-9 mg, caused a marked hypotension and increase of cardiac output in 5 cases. Though left ventricular work was reduced or unchanged after the drug, myocardial blood flow increased markedly, coronary resistance decreased and coronary A-V [atrioventricular] O2 difference decreased by about 50% indicating coronary vasodilation. When compared with the available data on the effects of hydrazinophthalazine, L 6150 appeared to have qualitatively similar effects, but a somewhat greater direct coronary vasodilator effect.

(PDF 0-2 workdays service: $29.90)

Accession: 006574940

PMID: 1027634



Related references

Hemodynamic activity of L 6150. Systemic and coronary circulation. Naunyn-Schmiedeberg's Archives of Pharmacology 279(3): 301-312, 1973

Hemodynamic activity of l 6150 3 hydrazino 6 n n bis 2 hydroxyethylamino pyridazine systemic and coronary circulation. Naunyn Schmiedeberg's Archives of Pharmacology 279(3): 301-312, 1973

Effects of brain (B-type) natriuretic peptide on coronary artery diameter and coronary hemodynamic variables in humans: comparison with effects on systemic hemodynamic variables. Journal of the American College of Cardiology 25(2): 342-348, 1995

Clinical and hemodynamic study of a new vaso dilator drug l 6150 3 bis 2 hydroxyethylamino 6 hydrazino pyridazine in man. Clinical Science & Molecular Medicine 51(SUPPL 3): 601S-603S, 1976

Acute systemic and coronary hemodynamic effects of chlorothiazide in subjects with systemic arterial hypertension. American Journal of Cardiology 10: 183-186, 1962

Hemodynamic effects of the new anti hypertensive agent 3 hydrazino 6 n n bis 2 hydroxyethylamino pyridazine di hydro chloride l 6150. Naunyn-Schmiedebergs Archiv fuer Pharmakologie 269(2-4): 390, 1971

The effects of propafenone a new class ic antiarrhythmic drug on systemic and coronary circulation hemodynamic study of 10 patients in the basal state and under auricular electrical stimulation before and after intravenous injection of propafenone. Annales de Cardiologie et d'Angeiologie 35(2): 119-122, 1986

Systemic and coronary hemodynamic effects of diazepam in patients with normal and diseased coronary arteries. Circulation 50(6): 1210-1216, 1974

Hemodynamic and oxygen transport responses to exercise in hypertensive and normotensive age peers: effects of hypotensive drug treatments. American Journal of the Medical Sciences 253(2): 180-193, 1967

Systemic and coronary hemodynamic effects of alpha 1 adrenoceptor blockade in patients with coronary artery disease. British Journal of Clinical Pharmacology 20(3): 247P, 1985